Effect of CIK on long-term survival and hepatitis B reactivation in the treatment of hepatocellular carcinoma after RFA and TACE
10.3760/cma.j.issn.1007-631X.2016.10.017
- VernacularTitle:射频消融及肝动脉化疗栓塞术后自体杀伤细胞回输对肝癌患者远期生存及HBV激活的影响
- Author:
Jiaobang XU
;
Guozheng PAN
;
Jian ZHANG
;
Long HAO
;
Shilei LI
;
Qingzhong YUAN
- Publication Type:Journal Article
- Keywords:
Carcinoma,hepatocellular;
Cytokine-induced killer cells;
Hepatitis B virus
- From:
Chinese Journal of General Surgery
2016;31(10):854-858
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate effects of autologous cytokine-induced killer cell (CIK) transfusion on the survival and hepatitics B virus (HBV) reactivation after radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE).Methods A retrospective analysis was conducted on 185 patients with hepatocellular carcinoma treated from Mar 2007 to Oct 2013.Patients were divided into study group (RFA,TACE,CIK) of 98 cases and control group (RFA,TACE) of 87 cases.According to tumor size,numbers and vascular invasion,patients were stratified into 4 subgroups:the high and the low risk group respectively with tumor ≤ 5 cm and ＞ 5 cm.Results The 1-,3-,5-year survival rate between study and control group were not significantly different:75.5％ (74/98),57.1％ (56/98),20.4％ (20/98) vs.71.2％ (62/87),54.0％ (47/87),21.8％ (19/87) (P ＞ 0.05).Only the study group's 1-,3-,5-year survival rate of high risk patients with tumor ≤ 5 cm were higher than the control group:75.0％ (21/28),53.6％ (15/28),35.7 ％ (10/28) vs.61.9％ (13/21),42.9％ (9/21),23.5％ (5/21) (P ＜ 0.05).The incidence of HBV reactivation was lower in dunantiviral patients who received CIK therapy than those who had 6.0％ (3/50) vs.23.5％ (12/61) (P ＜ 0.05).Conclusion Postoperative adjuvant CIK therapy with tumor≤5cm after RFA combined with TACE was beneficial to the survival of high risk patients and decreased the risk of HBV reactivation.
